Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, 4 Raja S.C. Mullick Road, Jadavpur, Kolkata 700032, India.
Expert Rev Vaccines. 2012 Jul;11(7):783-5. doi: 10.1586/erv.12.50.
Leishmanization or live vaccination, the gold standard for immunoprophylactic success against cutaneous leishmaniasis, has been abandoned for safety reasons. Killed but metabolically active (KBMA) Leishmania, a new class of whole-cell vaccine, holds promise for safe vaccination. Amotosalen (S-59)-treated and UVA-irradiated Leishmania major and Leishmania infantum chagasi (KBMA-Lic) were rendered replication-incompetent and incapable of causing disease; this was demonstrated convincingly by sensitive techniques. However, the immune response and the level of protection elicited by vaccination with both live Lic and KBMA-Lic in BALB/c mice are less than optimal and warrant further studies to establish their potentiality as an effective vaccine strategy against visceral leishmaniasis.
利什曼化或活体疫苗接种是预防皮肤利什曼病免疫成功的金标准，但由于安全性原因已被放弃。已死亡但代谢活跃（KBMA）的利什曼原虫是一种新型全细胞疫苗，有望实现安全接种。用氨甲蝶呤（S-59）处理和 UVA 照射的大沙鼠利什曼原虫和恰加斯利什曼原虫（KBMA-Lic）已被证明失去了复制能力，不会引起疾病；这一点通过敏感技术得到了令人信服的证明。然而，用活的 Lic 和 KBMA-Lic 对 BALB/c 小鼠进行疫苗接种所引起的免疫反应和保护水平并不理想，需要进一步研究以确定它们作为一种有效的内脏利什曼病疫苗策略的潜力。
